Medical and Maintenance Treatments for Vitiligo.
Medical treatments alone, or in combination with phototherapy, are key approaches for treating nonsegmental vitiligo and, to a lesser extent, segmental vitiligo. The treatments are useful for halting disease progression and have been proven effective for inducing repigmentation and decreasing risk of relapses. Although the treatments have side effects and limitations, vitiligo often induces a marked decrease in quality of life and in most cases the risk:benefit ratio is in favor of an active approach. Systemic and topical agents targeting the pathways involved in loss of melanocytes and in differentiation of melanocyte stem cells should provide more effective approaches in the near future.
Department of Dermatology and INSERM U1065, Team 12, C3M, Archet 2 Hospital, University Hospital of Nice, 150 Route de Ginestière, Nice 06200, France. Electronic address: passeron@unice.fr.
Thierry
T
Passeron
D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D065095:Calcineurin Inhibitors / Q000627:therapeutic use*; D015232:Dinoprostone / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D028022:Low-Level Light Therapy; D008727:Methotrexate / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D010120:Oxytocics / Q000627:therapeutic use; D010789:Phototherapy; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014807:Vitamin D / Q000031:analogs & derivatives; D014820:Vitiligo / Q000628:therapy*; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D010120:Oxytocics; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D014807:Vitamin D; D000521:alpha-MSH; C479163:tofacitinib; D008911:Minocycline; D015232:Dinoprostone; C534526:afamelanotide; D008727:Methotrexate
Calcineurin inhibitors; Medical treatments; Methotrexate; Sytemic steroids; Topical steroids; Vitiligo